Objective:  To  determine the efficacy and safety ofmidazolam given as a continuous infusion in the treat-ment of refractory generalized status epilepticus(RGSE).Method: Prospective, open study. Eleven patients withRGSE, who received intravenous doses of 0.3 mg/kgof diazepam (three times at 5 min intervals), 20 mg/kgof phenytoin, and 20 mg/kg of phenobarbital that failedto bring the episode under control were administereda bolus of midazolam (200 mg/kg iv) followed by a con-tinuous infusion at 1 mg/kg/min. The dose was in-creased every 15 min until the episode of seizure wasbrought under control. Time to control seizures, infu-sion rate, and side-effects were monitored.Results:  The mean age of the patients was 22.8 yrs(range 16 yrs to 73 yrs; 5 females and 6 males). In tenof the patients, seizures were completely controlled ina mean time of 2.1 hrs (range 0.4 hrs to 4.5 hrs), withan infusion rate of 8.4 mg/kg/min (range 3 to 12). Inone patient seizures did not stop. None of the patientshad clinically important changes in blood pressure,heart rate, oxygen saturation  or respiratory status at-tributable to the use of midazolam. The mean time tofull consciousness for patients after stopping the in-fusion was 1.6 hrs (range 2 to 8.5).Conclusion: Midazolam is an effective and safe drugto control RGSE and may represent a substantial im-provement over current therapeutic approaches suchas pentobarbital anesthesia.Key words: Midazolam, anticonvulsants, status epilepticus,neurologic emergencies.